|
SELECT PUBLICATIONS
Bartlett JM. Pharmacodiagnostic testing in breast cancer: Focus on HER2 and trastuzumab
therapy. Am J Pharmacogenomics 2005;5(5):303-15. Abstract
BCIRG. Interim analysis of phase III study shows Taxotere® (docetaxel)-based chemotherapy
regimens combined with Herceptin® (trastuzumab) significantly improved
disease free survival in early-stage HER2-positive breast cancer [press release]. September 15, 2005. Abstract
Burstein HJ. The distinctive nature of HER2-positive breast cancer. N Engl J Med 2005;353:1652-54. No abstract available
Buzdar AU et al. Significantly higher pathologic complete response remission rate after
neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy:
Results of a randomized trial in human epidermal growth factor receptor 2-positive
operable breast cancer. J Clin Oncol 2005;23:3656-59. Abstract
De Laurentiis M et al. Targeting HER2 as a therapeutic strategy for breast cancer: A
paradigmatic shift of drug development in oncology. Ann Oncol 2005;16(Suppl 4):iv7-iv13.
Abstract
Ewer MS et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based
on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6.
Abstract
Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734-36. No abstract available
Klein PM, Dybdal N. Trastuzumab and cardiac dysfunction: Update on preclinical
studies. Semin Oncol 2003;30(5 Suppl 16):49-53. Abstract
Mamounas EP. Can we approach zero relapse in breast cancer? Oncologist 2005;10 Suppl 2:9-
17. Abstract
Perez EA. Further analysis of NCCTG-N9831. Presentation. Proc ASCO 2005a. No abstract
available
Perez EA et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant
trastuzumab trial. Presentation. ASCO 2005b;Abstract 556.
Perez EA et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection
fraction in patients with breast cancer in the North Central Cancer Treatment Group
N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004;22(18):3700-4. Abstract
Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or
without trastuzumab as adjuvant therapy for patients with HER-2 positive operable
breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO
2005. No abstract available
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive
breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Seidman A et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin
Oncol 2002;20(5):1215-21. Abstract
Slamon DJ. Antibody-based therapeutics: More than a one-trick pony. Presentation. ASCO
2005. No abstract available
Suter TM et al. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the
treatment of metastatic breast cancer. Breast 2004;13(3):173-83. Abstract
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing
doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab
as adjuvant therapy in node-positive, human epidermal growth factor receptor
2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
|
